CORRECTING and REPLACING -- UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results
February 27, 2019 16:05 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline on February 25th by UNITY Biotechnology, Inc. [Nasdaq: UBX], please note that in the first paragraph of...
UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results
February 25, 2019 16:05 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [Nasdaq: UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
UNITY Biotechnology Expands Ongoing UBX0101 Phase 1 Study to Further Evaluate SASP Factors in Osteoarthritis of the Knee
January 22, 2019 16:05 ET
|
Unity Biotechnology, Inc.
- Results expected in the second quarter of 2019 - SAN FRANCISCO, Jan. 22, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics...
UNITY Biotechnology Announces Completion of UBX1967 License and Advance into IND-Enabling Studies for Age-Related Diseases of the Eye
January 03, 2019 16:52 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend human healthspan by slowing, halting or...
UNITY Biotechnology, Inc. Appoints Margo Roberts Ph.D. to Board of Directors
December 04, 2018 08:00 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
UNITY Biotechnology Announces Additional Cohort to Evaluate Higher Dose in Ongoing UBX0101 Phase 1 Study in Osteoarthritis of the Knee
December 03, 2018 17:30 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
UNITY Biotechnology, Inc. to Host Investor & Analyst Event on Cellular Senescence
November 13, 2018 08:00 ET
|
Unity Biotechnology, Inc.
- Event will be webcast live - SAN FRANCISCO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend...
UNITY Biotechnology, Inc. Reports Third Quarter 2018 Financial Results
November 07, 2018 16:05 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
UNITY Biotechnology, Inc. to Announce Third Quarter 2018 Financial Results
October 31, 2018 16:05 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
UNITY Biotechnology, Inc. to Participate in the Cantor Fitzgerald Annual Global Healthcare Conference
September 24, 2018 16:05 ET
|
Unity Biotechnology, Inc.
SAN FRANCISCO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...